{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:04:17Z","timestamp":1787025857128,"version":"build-2736575974"},"reference-count":29,"publisher":"Centers for Disease Control and Prevention (CDC)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Emerg. Infect. Dis."],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.3201\/eid3102.240251","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T13:09:07Z","timestamp":1737464947000},"source":"Crossref","is-referenced-by-count":3,"title":["Adaptive Design for Phase II\/III Platform Trial of Lassa Fever Therapeutics"],"prefix":"10.3201","volume":"31","author":[{"given":"Josephine","family":"Bourner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Vaillant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex Paddy","family":"Abdel Salam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Jaspard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Fritzell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shevin T.","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom E.","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ramharter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nnennaya","family":"Ajayi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvanus","family":"Okogbenin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Erameh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Samuels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oladele Oluwafemi","family":"Ayodeji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armand","family":"Sprecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronner P.","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tansy","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Olliaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the WALC Work Package 2 Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1822","reference":[{"key":"key-10.3201\/eid3102.240251-202501211053-R1","first-page":"2023","article-title":"Lassa fever situation report.","volume":"52","author":"Nigeria Centre for Disease Control","year":"2023","journal-title":"Epi Week."},{"key":"key-10.3201\/eid3102.240251-202501211053-R2","doi-asserted-by":"publisher","first-page":"103673","DOI":"10.1016\/j.dib.2019.01.021","article-title":"Data set on Lassa fever in post-conflict Sierra Leone.","volume":"23","author":"Shaffer","year":"2019","journal-title":"Data Brief"},{"key":"key-10.3201\/eid3102.240251-202501211053-R3","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.ijid.2022.07.006","article-title":"Epidemiological characteristics of Lassa fever cases in Liberia: a retrospective analysis of surveillance data, 2019-2020.","volume":"122","author":"Jetoh","year":"2022","journal-title":"Int J Infect Dis"},{"key":"key-10.3201\/eid3102.240251-202501211053-R4","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.3390\/v12101062","article-title":"A sporadic and lethal Lassa fever case in Forest Guinea, 2019.","volume":"12","author":"Magassouba","year":"2020","journal-title":"Viruses"},{"key":"key-10.3201\/eid3102.240251-202501211053-R5","doi-asserted-by":"publisher","first-page":"8242313","DOI":"10.1155\/2017\/8242313","article-title":"Emergence of Lassa fever disease in northern Togo: report of two cases in Oti District in 2016.","volume":"2017","author":"Patassi","year":"2017","journal-title":"Case Rep Infect Dis"},{"key":"key-10.3201\/eid3102.240251-202501211053-R6","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1080\/22221751.2020.1796528","article-title":"Lassa fever in Benin: description of the 2014 and 2016 epidemics and genetic characterization of a new Lassa virus.","volume":"9","author":"Yadouleton","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"key-10.3201\/eid3102.240251-202501211053-R7","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1093\/trstmh\/trv047","article-title":"Mapping the zoonotic niche of Lassa fever in Africa.","volume":"109","author":"Mylne","year":"2015","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"key-10.3201\/eid3102.240251-202501211053-R8","doi-asserted-by":"publisher","first-page":"e0009788","DOI":"10.1371\/journal.pntd.0009788","article-title":"Clinical characterization of Lassa fever: A systematic review of clinical reports and research to inform clinical trial design.","volume":"15","author":"Merson","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"key-10.3201\/eid3102.240251-202501211053-R9","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/S1473-3099(18)30121-X","article-title":"Clinical and laboratory predictors of Lassa fever outcome in a dedicated treatment facility in Nigeria: a retrospective, observational cohort study.","volume":"18","author":"Okokhere","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"key-10.3201\/eid3102.240251-202501211053-R10","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1016\/S2214-109X(20)30518-0","article-title":"Lassa fever outcomes and prognostic factors in Nigeria (LASCOPE): a prospective cohort study.","volume":"9","author":"Duvignaud","year":"2021","journal-title":"Lancet Glob Health"},{"key":"key-10.3201\/eid3102.240251-202501211053-R11","doi-asserted-by":"publisher","first-page":"262","DOI":"10.2105\/AJPH.2017.304186","article-title":"Mortality among confirmed Lassa fever cases during the 2015\u20132016 outbreak in Nigeria.","volume":"108","author":"Buba","year":"2018","journal-title":"Am J Public Health"},{"key":"key-10.3201\/eid3102.240251-202501211053-R12","unstructured":"Nigeria Centre for Disease Control. National Guideline for Lassa Fever Case Management. 2018 [cited 2024 Feb 20]. https:\/\/ncdc.gov.ng\/ncdc.gov.ng\/themes\/common\/docs\/protocols\/92_1547068532.pdf"},{"key":"key-10.3201\/eid3102.240251-202501211053-R13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJM198601023140104","article-title":"Lassa fever. Effective therapy with ribavirin.","volume":"314","author":"McCormick","year":"1986","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid3102.240251-202501211053-R14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ijid.2019.07.015","article-title":"Ribavirin for the treatment of Lassa fever: A systematic review and meta-analysis.","volume":"87","author":"Eberhardt","year":"2019","journal-title":"Int J Infect Dis"},{"key":"key-10.3201\/eid3102.240251-202501211053-R15","doi-asserted-by":"publisher","first-page":"e1011","DOI":"10.1016\/j.ijid.2013.05.015","article-title":"Containing a Lassa fever epidemic in a resource-limited setting: outbreak description and lessons learned from Abakaliki, Nigeria (January-March 2012).","volume":"17","author":"Ajayi","year":"2013","journal-title":"Int J Infect Dis"},{"key":"key-10.3201\/eid3102.240251-202501211053-R16","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1093\/trstmh\/tru009","article-title":"Constraints in the diagnosis and treatment of Lassa Fever and the effect on mortality in hospitalized children and women with obstetric conditions in a rural district hospital in Sierra Leone.","volume":"108","author":"Dahmane","year":"2014","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"key-10.3201\/eid3102.240251-202501211053-R17","doi-asserted-by":"publisher","first-page":"20499361211058252","DOI":"10.1177\/20499361211058252","article-title":"Epidemiological trends of Lassa fever in Nigeria from 2015-2021: A review.","volume":"8","author":"Grace","year":"2021","journal-title":"Ther Adv Infect Dis"},{"key":"key-10.3201\/eid3102.240251-202501211053-R18","doi-asserted-by":"publisher","first-page":"e0010089","DOI":"10.1371\/journal.pntd.0010089","article-title":"A standardised Phase III clinical trial framework to assess therapeutic interventions for Lassa fever.","volume":"16","author":"Olayinka","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"key":"key-10.3201\/eid3102.240251-202501211053-R19","unstructured":"The International Severe Acute Respiratory and Emerging Infection Consortium. West Africa Lassa Fever Consortium (WALC) [cited 2024 Feb 20]. https:\/\/isaric.org\/research\/lassa-fever-resources\/walc"},{"key":"key-10.3201\/eid3102.240251-202501211053-R20","doi-asserted-by":"publisher","first-page":"122","DOI":"10.12688\/wellcomeopenres.19041.2","article-title":"The West Africa Lassa fever Consortium pre-positioned protocol for a Phase II\/III adaptive, randomised, controlled, platform trial to evaluate multiple Lassa fever therapeutics.","volume":"8","author":"Bourner","year":"2023","journal-title":"Wellcome Open Res"},{"key":"key-10.3201\/eid3102.240251-202501211053-R21","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1164\/rccm.201503-0584OC","article-title":"Hospital incidence and outcomes of the acute respiratory distress syndrome using the Kigali modification of the Berlin definition.","volume":"193","author":"Riviello","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"key-10.3201\/eid3102.240251-202501211053-R22","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The Third International Consensus definitions for sepsis and septic shock (sepsis-3).","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"key-10.3201\/eid3102.240251-202501211053-R23","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/S1473-3099(18)30121-X","article-title":"Clinical and laboratory predictors of Lassa fever outcome in a dedicated treatment facility in Nigeria: a retrospective, observational cohort study.","volume":"18","author":"Okokhere","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"key-10.3201\/eid3102.240251-202501211053-R24","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/eurheartj\/ehr352","article-title":"The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities.","volume":"33","author":"Pocock","year":"2012","journal-title":"Eur Heart J"},{"key":"key-10.3201\/eid3102.240251-202501211053-R25","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1177\/216847900604000413","article-title":"Sample size reestimation: a review and recommendations.","volume":"40","author":"Chuang-Stein","year":"2006","journal-title":"Drug Inf J"},{"key":"key-10.3201\/eid3102.240251-202501211053-R26","doi-asserted-by":"publisher","first-page":"e0010289","DOI":"10.1371\/journal.pntd.0010289","article-title":"Ribavirin for treating Lassa fever: A systematic review of pre-clinical studies and implications for human dosing.","volume":"16","author":"Salam","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"key":"key-10.3201\/eid3102.240251-202501211053-R27","doi-asserted-by":"publisher","first-page":"e841","DOI":"10.1093\/cid\/ciac578","article-title":"Pharmacokinetics of ribavirin in the treatment of Lassa fever: an observational clinical study at the Irrua Specialist Teaching Hospital, Edo State, Nigeria.","volume":"76","author":"Groger","year":"2023","journal-title":"Clin Infect Dis"},{"key":"key-10.3201\/eid3102.240251-202501211053-R28","doi-asserted-by":"publisher","first-page":"856","DOI":"10.4269\/ajtmh.20-1624","article-title":"Evaluation of three clinical prediction tools to predict mortality in hospitalized patients with Lassa fever.","volume":"107","author":"Chiosi","year":"2022","journal-title":"Am J Trop Med Hyg"},{"key":"key-10.3201\/eid3102.240251-202501211053-R29","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/jmv.1890260204","article-title":"Hematologic dysfunction in Lassa fever.","volume":"26","author":"Fisher-Hoch","year":"1988","journal-title":"J Med Virol"}],"container-title":["Emerging Infectious Diseases"],"original-title":[],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T13:09:09Z","timestamp":1737464949000},"score":1,"resource":{"primary":{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/31\/2\/24-0251_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"URL":"https:\/\/doi.org\/10.3201\/eid3102.240251","relation":{},"ISSN":["1080-6040","1080-6059"],"issn-type":[{"value":"1080-6040","type":"print"},{"value":"1080-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]}}}